The disruptive potential of CRISPR-Cas9 was crystal clear from the very first publication on the subject. Since then, the diversity of possible uses has exploded. The feasibility and subsequent translation into real world applications in the medical field has proceeded at an unprecedented speed. In this year’s RegMed forum on November 25th 2021 in Berlin, Germany, academic researchers and industry scientists will shed light on the potential of CRISPR-Cas9 in medicine.
- Leila Amini - BCRT/BeCAT - CRISPR-based immune cell therapies (title tbc)
- Andre Cohnen - Bayer AG - Novel CRISPR enzymes from nature and lab (title tbc)
- Juergen Foell - University of Regensburg (title tbc)
- Michael Kaminski - MDC/Charité - CRISPR-based diagnostics (title tbc)
- Simone Spuler - MDC/Charité - CRISPR-based therapies for genetic muscle disorders (title tbc)
- Dimitrios Wagner - BCRT/BeCAT – Evolution of the CRISPR-Cas9 technology
Here you find the preliminary agenda: LINK.
We are looking forward to meet you in person in Berlin and to have exciting discussions.
About the event
The Berlin Institute of Health (BIH) Center for Regenerative Therapies (BCRT) and the Cluster Health Capital Berlin-Brandenburg are jointly organising the international RegMed Forum since 2014.
This event series provide the opportunity to hear and discuss science in the field of regenerative medicine - from basic research to clinical implementation and industrialization. In addition to a comprehensive scientific program there will be opportunities to discuss and network with industry and research groups in the regenerative medicine field.
About BIH Center for Regenerative Medicine (BCRT)
The research landscape of Berlin/Brandenburg has developed into one of the most important international clusters for regenerative medicine. A major contribution to this development has been the BIH Center for Regenerative Therapies (BCRT) - an interdisciplinary clinical translational center operated by the Berlin Institute of Health (BIH).
The primary focus of the BCRT is the development of novel methods to promote endogenous regeneration to address acute and chronic diseases of the immune, musculoskeletal and cardiovascular systems. This includes using cells, biomaterials and biological factors or a combination thereof to provide long term and possibly even curative treatments. With respect to the development and implementation of innovative therapies and products from the BCRT, the first potential success story for a novel regenerative product is starting to emerge. Virus-specific T-cell products for long-term protection against serious infections are being evaluated in onsite clinical studies for treatment of patients with a weakened immune system. Following the concept of refined translation, i.e. iterative incorporation of (pre-) clinical research findings into product development, and the use of biomarkers, the BCRT is actively pushing further treatment concepts towards clinical evaluation. This also includes new cell-based therapies for heart disease and muscle injuries.
About the Cluster Health Capital
The German capital region is one of the world's leading locations for the healthcare industry, healthcare, and the life sciences. Leading global companies, renowned scientists, first-class hospitals, innovative start-ups, and specialists from all over the world work together in Berlin-Brandenburg each day to deliver the very best goods and services for the regional and global healthcare markets.
The cluster management team at Berlin Partner for Business and Technology and Brandenburg Economic Development Corporation (WFBB) drives networking and the technology transfer in the region and supports international companies interested in relocating to the German capital region.
Compliance with Corona rules
The event will take place in compliance with the currently valid Corona rules according to the Ordinance (see here).
Due to that we only have limited space for onsite participants. Please only register for this onsite event in case you are willing to come onsite on Nov 25th. In case the Corona rules will change we might have to change the event into a hybrid or virtual mode.
We encourage you to use the Corona-Warn-App and follow the the currently valid Corona rules (see above).